Literature DB >> 30033198

Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression.

Jingjing Cong1, Xianwei Wang1, Xiaohu Zheng1, Dong Wang1, Binqing Fu2, Rui Sun2, Zhigang Tian3, Haiming Wei4.   

Abstract

Natural killer (NK) cells are effector lymphocytes with pivotal roles in the resistance against various tumors; dysfunction of NK cells often results in advanced tumor progression. Tumors develop in three stages comprising initiation, promotion, and progression, but little is known about the interrelationships between NK cells and tumor cells at different stages of tumor development. Here, we demonstrated that NK cells prevented tumor initiation potently but did not prevent tumor promotion or tumor progression in Kras-driven lung cancer. Moreover, loss of the antitumor effect in NK cells was closely associated with their dysfunctional state during tumor promotion and progression. Mechanistically, aberrant fructose-1,6-bisphosphatase (FBP1) expression in NK cells elicited their dysfunction by inhibiting glycolysis and impairing viability. Thus, our results show dynamic alterations of NK cells during tumor development and uncover a novel mechanism involved in NK cell dysfunction, suggesting potential directions for NK cell-based cancer immunotherapy involving FBP1 targeting.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FBP1; NK cell dysfunction; glycolysis; lung cancer

Mesh:

Substances:

Year:  2018        PMID: 30033198     DOI: 10.1016/j.cmet.2018.06.021

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  93 in total

Review 1.  Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?

Authors:  Gabriele Grasmann; Elisabeth Smolle; Horst Olschewski; Katharina Leithner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 2.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 3.  Proteins moonlighting in tumor metabolism and epigenetics.

Authors:  Lei Lv; Qunying Lei
Journal:  Front Med       Date:  2021-01-02       Impact factor: 4.592

Review 4.  Mutually assured destruction: the cold war between viruses and natural killer cells.

Authors:  Ayad Ali; Ivayla E Gyurova; Stephen N Waggoner
Journal:  Curr Opin Virol       Date:  2019-03-13       Impact factor: 7.090

Review 5.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

6.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Authors:  Huang Zhu; Robert H Blum; Davide Bernareggi; Eivind Heggernes Ask; Zhengming Wu; Hanna Julie Hoel; Zhipeng Meng; Chengsheng Wu; Kun-Liang Guan; Karl-Johan Malmberg; Dan S Kaufman
Journal:  Cell Stem Cell       Date:  2020-06-11       Impact factor: 24.633

Review 7.  Innate lymphoid cell memory.

Authors:  Xianwei Wang; Hui Peng; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2019-02-22       Impact factor: 11.530

8.  Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance.

Authors:  Xiaohu Zheng; Yeben Qian; Binqing Fu; Defeng Jiao; Yong Jiang; Peng Chen; Yiqing Shen; Huafeng Zhang; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Nat Immunol       Date:  2019-10-21       Impact factor: 25.606

Review 9.  Metabolism of immune cells in cancer.

Authors:  Robert D Leone; Jonathan D Powell
Journal:  Nat Rev Cancer       Date:  2020-07-06       Impact factor: 60.716

Review 10.  TGF-β links glycolysis and immunosuppression in glioblastoma.

Authors:  Lingli Gong; Li Ji; Daxing Xu; Jingjing Wang; Jian Zou
Journal:  Histol Histopathol       Date:  2021-07-29       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.